Galapagos Appoints Dr. Paulo Fontoura as Independent Non-Executive Director
Galapagos NV has announced the appointment of Dr. Paulo Fontoura as an independent non-executive director to its board, effective from February 9, 2026. He replaces Dr. Susanne Schaffert, who left the board on November 1, 2025.
Appointment Details
Dr. Paulo Fontoura was appointed by co-option as an independent non-executive director to the board of Galapagos NV, effective February 9, 2026. Dr. Fontoura brings 20 years of experience in the pharmaceutical industry, with deep expertise in neurology, immunology, ophthalmology, and rare diseases. He currently holds the position of Chief Medical Officer at Xaira. Previously, he served as SVP and Global Head at Roche, where he led clinical development in the fields of neuroscience, immunology, ophthalmology, and rare diseases.
Replacement Information
Dr. Paulo Fontoura replaces Dr. Susanne Schaffert, who effectively left the board on November 1, 2025, as previously announced in the press release dated October 30, 2025.
